📊 INTS Key Takeaways
Is Intensity Therapeutics, Inc.. (INTS) a Good Investment?
Intensity Therapeutics is a pre-revenue clinical-stage biopharmaceutical company with no sales generation, demonstrating severe cash burn of $9.2M annually. With only $11.9M in cash and negative operating income of $12M, the company has approximately 1.3 years of runway at current burn rates, creating existential liquidity risk. Negative returns on equity (-97.7%) and assets (-82.3%), combined with deteriorating financial position, indicate unsustainable operations without significant capital raises or clinical breakthroughs.
Intensity Therapeutics remains a pre-revenue biotech with persistent operating and net losses, negative cash flow, and deeply negative returns on equity and assets, which makes the fundamental profile weak despite some year-over-year loss improvement. Its balance sheet is currently a relative strength, with nearly all assets held in cash, no long-term debt, and strong liquidity, but the business still depends on converting that cash into clinical and commercial progress before runway tightens.
Why Buy Intensity Therapeutics, Inc.. Stock? INTS Key Strengths
- Strong liquidity position with $11.9M cash equivalent to total stockholders equity
- Zero debt burden providing financial flexibility for restructuring or strategic alternatives
- Minimal liabilities ($2.2M) reducing near-term financial obligations
- Strong liquidity with $11.92M in cash and current and quick ratios of 5.92x
- No long-term debt and minimal leverage reduce balance sheet risk
- Net loss improved year over year, indicating some cost-control or expense timing benefit
INTS Stock Risks: Intensity Therapeutics, Inc.. Investment Risks
- No revenue generation with pre-clinical stage pharmaceutical operations creating unlimited burn scenario
- Severe cash burn rate of $9.2M annually implies only ~1.3 years of operational runway at current rates
- Pre-revenue stage with no indication of product commercialization timeline or clinical trial success rates
- Persistent negative profitability (-$12M operating loss) with no clear path to breakeven
- Dilution risk from future equity financing requirements to sustain operations
- No revenue base means growth quality and commercial viability are still unproven
- Operating cash burn of $9.23M materially pressures cash runway
- Very negative ROE and ROA show poor current capital efficiency and asset productivity
Key Metrics to Watch
- Cash burn rate and runway remaining until liquidity exhaustion
- Clinical trial progress and regulatory pathway advancement
- Capital raise timing, size, and dilution percentage
- Operating cash flow improvement trajectory toward breakeven
- Quarterly operating cash burn relative to cash balance
- Any transition from pre-revenue status to sustainable collaboration, licensing, or product revenue
Intensity Therapeutics, Inc.. (INTS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.92x current ratio provides a solid financial cushion.
INTS Profit Margin, ROE & Profitability Analysis
INTS vs Healthcare Sector: How Intensity Therapeutics, Inc.. Compares
How Intensity Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Intensity Therapeutics, Inc.. Stock Overvalued? INTS Valuation Analysis 2026
Based on fundamental analysis, Intensity Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Intensity Therapeutics, Inc.. Balance Sheet: INTS Debt, Cash & Liquidity
INTS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Intensity Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-29.24 indicates the company is currently unprofitable.
INTS Revenue Growth, EPS Growth & YoY Performance
Intensity Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
INTS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Intensity Therapeutics, Inc.. (CIK: 0001567264)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INTS
What is the AI rating for INTS?
Intensity Therapeutics, Inc.. (INTS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INTS's key strengths?
Claude: Strong liquidity position with $11.9M cash equivalent to total stockholders equity. Zero debt burden providing financial flexibility for restructuring or strategic alternatives. ChatGPT: Strong liquidity with $11.92M in cash and current and quick ratios of 5.92x. No long-term debt and minimal leverage reduce balance sheet risk.
What are the risks of investing in INTS?
Claude: No revenue generation with pre-clinical stage pharmaceutical operations creating unlimited burn scenario. Severe cash burn rate of $9.2M annually implies only ~1.3 years of operational runway at current rates. ChatGPT: No revenue base means growth quality and commercial viability are still unproven. Operating cash burn of $9.23M materially pressures cash runway.
What is INTS's revenue and growth?
Intensity Therapeutics, Inc.. reported revenue of N/A.
Does INTS pay dividends?
Intensity Therapeutics, Inc.. does not currently pay dividends.
Where can I find INTS SEC filings?
Official SEC filings for Intensity Therapeutics, Inc.. (CIK: 0001567264) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INTS's EPS?
Intensity Therapeutics, Inc.. has a diluted EPS of $-8.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INTS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Intensity Therapeutics, Inc.. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INTS stock overvalued or undervalued?
Valuation metrics for INTS: ROE of -97.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INTS stock in 2026?
Our dual AI analysis gives Intensity Therapeutics, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INTS's free cash flow?
Intensity Therapeutics, Inc..'s operating cash flow is $-9.2M, with capital expenditures of N/A.
How does INTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -97.7% (avg: 15%), current ratio 5.92 (avg: 2).